UBS initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $12 price target As one of the more potent anti-fibrotics UBS has ...

s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, (GLOBE ...

STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expres ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress ... Cancers Symposium® will focus on treatment strategies in early-stage lung cancers, ...

Shareholders That Lost Money on Elanco Animal Health Incorporated (ELAN) Should Contact Levi & Korsinsky About Pending Class Action - ELAN ...

Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") of a class action securities ...

Specific types of immune cells unleashed by cancer immunotherapy appear to cause myocarditis, an inflammatory condition that can weaken the heart, researchers report.

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through ...